Our Team – KBP Biosciences

Our Team

  Management Team


|Wilson W. Cheung, Chief Financial Officer

Wilson W. Cheung joined KBP Biosciences in April 2018 and serves as its Chief Financial Officer. Prior to joining KBP, Mr. Cheung was Senior Vice President and CFO of SciClone Pharmaceuticals, Inc. a China-based US-listed specialty pharma company, where he drove the company’s growth and profitability for the past 4 years, and led to a successful sale. Prior to SciClone, Mr. Cheung served in various positions at Velti plc, a publicly traded global mobile marketing software-as-a-service provider, including most recently as Chief Compliance Officer, Asia Pacific and previously as Chief Financial Officer and led their Nasdaq IPO. Prior to Velti, Mr. Cheung served as Chief Financial Officer at AXT, Inc., a California-based, publicly traded manufacturer of high performance semiconductor substrates. Mr. Cheung holds a B.A. degree from the University of California, Los Angeles (UCLA), and is a Certified Director of Corporate Governance from UCLA’s Executive Program. He is a member of the American Institute of Certified Public Accountants and a California Certified Public Accountant (inactive).

|Fred Yang, PhD, Chief Development Officer

Fred leads development of medical strategies of the company. In this capacity Fred provides leadership and insights of medical development of the company’s clinical stage compounds.

Fred has almost 20 years of experience in clinical research and drug development, with expertise focusing on statistics and quantitative science. He assumed increasing responsibilities in both Big Pharma (Abbott, Pharmacia, GSK etc.) and small biotech (Discovery Labs), overseeing biostatistics as well as trial conduct and strategic planning. He had successful end-to-end development and worldwide regulatory experiences. His therapeutic experiences range from diabetes, CV, arthritis, oncology and neonatal care, with many publications.

Fred is currently adjunct associate professor at Drexel University Medical School. He is also a consultant for International Breast Cancer Research Foundation (IBCRF).

Fred received his undergraduate education at Peking University and his Ph.D degree from University of Wisconsin.

|Vincent J. Benn, PhD, MBA, Vice President, Regulatory & Medical Affairs

Vince brings more than 30 years of clinical and regulatory drug and biologics development experience to KBP BioSciences. Previously, he was Vice President Clinical & Regulatory Affairs at Essential Pharmaceuticals, Vice President Worldwide Clinical Operations at Discovery Labs, and Global Clinical Program Director at Aventis Behring LLC.  Previous clinical research projects span wide range of therapeutic areas, such as immunology, allergy, asthma, rheumatoid arthritis, and cardiology in several pharmaceutical companies including Pharmacia, Ortho, Rhone-Poulenc Rorer, and Merck. He has developed and defended clinical development plans before FDA, EMEA, MCA, MPA, and the Paul Erlich Institute (PEI).

He received his A.B. in Biological Science and English, M.S. in Physiology and Zoology, and Ph.D in Immunology from Rutgers University. He received additional training in clinical immunology at Harvard Medical School and The University of Texas.  He completed his M.B.A at the Fox School of Management at Temple University.  In addition, he was Regulatory Affairs Certified (R.A.C.) by the Regulatory Affairs Professional Society.

|Jay (Xu-Jie) Zhang, PhD, Vice President, Biology

Dr. Zhang graduated from Heinrich Heine University in Düsseldorf, Germany with a Ph.D. in Toxicology / Toxicokinetics, and a Master of Toxicology and a Bachelor of Public Health degree from Tongji Medical University. Dr. Zhang has many years of experience in pharmaceutical R&D. He has worked for several pharmaceutical R&D companies including Pfizer Pharmaceuticals.

An enthusiastic and goal oriented scientific leader in Drug Metabolism and Pharmacokinetics to support drug discovery and development; extensive training and hands-on experiences on drug metabolism and pharmacokinetics including in vitro enzymatic assays, in vitro and in vivo drug metabolism to assess metabolic clearance and metabolite profiling, species comparison and species selection for toxicology evaluations, drug-drug interaction assessment including drug metabolism enzyme inhibition/induction and IVIVE.

A successful project leader representing DMPK on drug discovery and development, interacting with scientists at multi-disciplinary team environment to achieve discovery and development project goals; authored DMPK and TK study reports and regulatory documentations (IB, IND/CTD); proficient with Phoenix WinNonlin, Gastro Plus, and other software such as Metasite, Meteor for drug metabolism and PKPD modeling/simulation, human PK and human dose projections; coordinating and supervising DMPK studies at CRO; current with regulatory guidelines on GLP, Safety Assessments, DDI, and Metabolites in Safety Test; excellent communication and interpersonal skills, effective collaboration and negotiation skills.

|Julie Pan, PhD, Vice President of Business Development

Julie Pan joined KBP in February 2018 after a 21-year career at AstraZeneca, Merck, GSK and Teva in the United States.  She currently serves as the Vice President of Business Development.   Julie experiences span from Drug Discovery, Drug Development, New Product Planning, Product Launch and Promotion, Business Development and Licensing, and Alliance Management.  Julie received her BS in Microbiology from Fudan University, Ph.D. in Biochemistry from Harvard University and MBA in Finance from Wharton School of Business.

|Linda Mooney, Vice President of Clinical Operations

Linda brings over 25 years of experience in Clinical Research and Development within small biotech companies, large pharmaceutical companies, as well as several years within a CRO. Over her career she has managed the execution of clinical trials in all phases of development and across many therapeutic areas, primarily in oncology as well as rare disease. Linda started her career performing In-Vitro and In-Vivo studies at Hoffmann La Roche and Schering-Plough. She then moved into Clinical Research working in Clinical Operations in positions of increasing responsibilities within Covance, Sanofi-Aventis, Agennix, Kyowa-Kirin Pharmaceuticals and most recently Insmed.

Board of Directors


|Zhenhua Huang, PhD/MBA, Founder/Board Chairman

Dr. Huang Zhenhua has been engaged in researching and developing innovative drugs for more than 20 years. He is the founder of KBP Biosciences Co., Ltd. developing drugs that uniquely meet unmet clinical needs.

Dr. Huang is a serial entrepreneur. He started his first venture in 1998. In 2002, he formed XuanZhu Pharma Co., Ltd. and sold it in 2012. Dr. Huang founded KBP Biosciences in 2011, dedicating himself to new molecular entity R&D. Under his leadership, KBP has built a strong pipeline for the global market, with multiple compounds in clinical development.

Dr. Huang obtained his PhD from Shenyang Pharmaceutical University, and EMBA from Peking University.

|Bing C. Wang, PhD/MBA, Board Director

Since March 2016, Bing Wang, Ph.D. has served as the CEO of Refuge Biotechnologies, a private biotech focused on developing next generation cell therapies using CRISPR interference technologies.  Dr. Wang was previously a healthcare investment banker for 9 years, most recently as a director of healthcare investment banking at Barclays Capital, where he served as strategic financial advisor for companies in the life sciences industry. Prior to working in Wall Street, Dr. Wang was a tenure-track assistant professor in the Electrical and Computer Engineering Department at the University of Connecticut, where he initiated and led research in optoelectronics and quantum cryptography. Dr. Wang received his B.S. in Applied Physics from Columbia University, Ph.D. in Electrical Engineering from Princeton University, and MBA from Columbia Business School.

|Benjamin Qiu, MBA, Board Director

Benjamin Qiu is Partner of Healthcare Investment with Advantech Capital/New Horizon Capital.

Ben has 14 years of experience in healthcare investment, consulting and hospital management.

Since joining New Horizon in 2013, Ben has led deals covering a wide spectrum across healthcare space including pharmaceutical/biological innovative drugs (Zai Lab, Harbour BioMed,Synermore, KBP), medical services (Arrail Dental), medical devices (HealForce), precision medicine (Genetron Health) and mobile health (Wiwide Youkang).

Before joining New Horizon, Ben led deals of Kangning Hospitals Group (HKSE:2120) and Arrail Dental, as a key member of a healthcare dedicated private equity fund – GL Capital.

As one of the founding members of Healthcare Advisory team at PwC China, Ben built up a client base including big pharma companies and investment firms, providing strategy, operation improvement consulting and deal due diligence services.

Ben started his healthcare career by working with Vancouver General Hospital as an analyst/project leader.

Ben graduated from University of British Columbia with an MBA in Finance, and Eastern China University of Technology with a Bachelor Degree in Power Engineering. Ben also holds Chartered Finance Analyst and Certified Management Accountant designations.

|Jin Wan, MBA, Board Director

Ms. Wan from SDICVC has over 10 years of experience in the healthcare industry and she has a deep understanding in all the sectors including new drugs, medical device and diagnosis, and medical service. Ms. Wan has in-depth experience in strategic planning, partnering, and mergers and acquisitions. Ms. Wan had four years of experience at Qiming Venture Partners, where she participated venture investment in Zai Lab, Berry Genomics, Canbridge and AmoyDx. Prior to that,Ms. Wan was a BD manager at Hutchison Medi Pharma (Shanghai) Ltd., a leading biopharmaceutical company in China. She participated in multiple clinical development projects, and contributed to the strategic collaborations between the Company and multinational pharmaceutical companies such as Eli Lilly and AstraZeneca.

Ms. Wan received a Bachelor of Pharmacy degree and a Master of Immunology Pharmacology degree from Wuhan University and Shanghai Institute of Materia Medica Chinese Academy of Sciences respectively. She holds her MBA degree from both China Europe International Business School and Duke University.

|Frederick Bernard Craves, PhD, Board Director

Fred Craves, PhD, is the Founder of Bay City Capital.  Since launching the firm in 1997, Fred has built Bay City Capital to become one of the world’s premier life science investment firms investing in nearly 100 companies and raising more than $1.6 billion.

As a leader in healthcare venture capital, Dr. Craves brings both scientific skills and deep operational expertise to the companies in which he invests. This allows him to source outstanding investment opportunities and to support exceptional management teams in creating value.  He has been associated with some of the most significant exits in the biopharmaceutical industry including Reliant Pharmaceuticals, a company he founded then sold to GlaxoSmithKline in 2007 in the single largest all-cash transaction for a venture backed biotech company at that time.  He has served as Executive Vice President of Schering Berlin, Chief Executive Officer and President of Berlex Biosciences, Founding Chairman of the Board and Chief Executive Officer of Codon, and co-founder of Creative Biomolecules.

Dr. Craves has been named to the Forbes Midas List, which recognizes the most successful investors in the venture capital asset class across both the technology and healthcare industries.  He currently serves on the Boards of Dermira, Imidomics Inc., Madrigal Pharmaceuticals, Reset Therapeutics and Twist Bioscience. Previous investments and board participation, in addition to Reliant, include Medarex, Incyte Pharmaceuticals, and Ion Torrent. He earned a BS in Biology from Georgetown University and a PhD in Pharmacology and Toxicology from the University of California, San Francisco.

Scientific Advisory Board


|George Bakris, MD, FASN, FAHA, FASH

George Bakris, MD, FASN, FAHA, FASH

Professor of Medicine, University of Chicago

Dr. Bakris conducts research related to hypertension, diabetes, and renal disease, and participates in clinical trials investigating the progression of diabetic renal disease and the effects of antihypertensive medications on renal disease progression. He was a principal investigator for several influential clinical trials, including AASK, GEMINI, GUARD, among many others. Dr. Bakris has served on the executive committees of multiple national reports and guidelines, including JNC VI, 1997, JNC 7, 2003, ISHIB (2003), NKF K/DOQI, and the American Diabetes Association Practice Guideline Committee (2002-2004).

Dr. Bakris is a member of numerous national committees and professional societies, and serves on many of their advisory boards, including those of the American Diabetes Association, American Society of Nephrology, the ISHIB, and the NKF. He is Past President of the American College of Clinical Pharmacology. Dr. Bakris currently serves on 14 editorial boards, including those of the American Journal of Hypertension, American Journal of Nephrology, Hypertension, and the Journal of Clinical Pharmacology and Ethnicity & Disease. His research has been published in more than 200 articles.

Dr. Bakris obtained his medical training at the Rosalind Franklin University of Medicine and Science and completed is residency training at the Mayo Clinic.

|Al Gianchetti, MBA

Al Gianchetti, MBA

Drug Development and Commercialization Strategy Advisor

Al Gianchetti is President and CEO of Longview Biopharm Partners.  He has over 25 years of experience in biopharmaceuticals in both R&D and US and global operations, including 7 years in the biotech environment and the remainder at GSK.  In VP, Chief Commercial Officer and in other leadership positions, he has sat on governance boards in sales, brand management, payer and managed care, drug discovery, drug development, business and corporate development and supply chain allowing him a broad view of the business.

Al was involved in development of 7 phase III programs and more than 10 phase I/II programs, led several US and global product launches and the acquisition/licensing of more than 10 products.  His therapeutic experience includes infectious diseases, psychiatry and neurosciences, cardio-metabolic-renal diseases including diabetes, oncology and urologic/men’s health.

|Frédéric Jaisser, MD, Ph.D

Frédéric Jaisser, MD, PhD

Head of Integrative Physiology and Pathophysiology Department, Cordeliers Research Centre, France

Dr. Jaisser joined the National Institute of Health and Medical Research (INSERM) in 1996 as Director of Research.  In 2003, he joined the Collège de France in Paris as an independent INSERM team and is currently the director of a team of the INSERM Unit U1138, at the Cordeliers Research Centre, Paris. Between 2010-2015, he was Scientific Delegate of the Pathophysiology Committee of the French National Research Agency. He has been recently appointed as French coordinator for Live Sciences in the ECOS French-South America exchange program.

The aim of his current studies is to improve the understanding of the pathophysiological roles and signaling pathways whereby the hormone aldosterone promotes pathologies in various organs including the kidney and the cardiovascular system. His work combines cellular and molecular approaches, animal physiology, pharmacological studies and has implications in human diseases. His interest includes translational research aimed to identify and validate biomarkers of mineralocorticoid receptor activation in cardiovascular and kidney diseases and novel therapeutic use of MR antagonists. He published 100 papers (H index 33, 2800 citations). Dr. Jaisser received his medical training and degrees from the Reims Medical School and was qualified as Nephrologist in 1990.

|Clare Kahn, PhD

Clare Kahn, PhD

Independent Adviser

Dr. Kahn has over 30 years of experience in the pharmaceutical industry with a proven leadership record in drug development, registration and life-cycle. She has held senior roles growing high functioning teams in research and development, regulatory strategy and business development at the portfolio level encompassing small molecules, biologicals and vaccines.

Dr. Kahn joined Pfizer in 2010 where she served as Vice President and Head of Global Regulatory Affairs for the $16bn Specialty Care Portfolio before expanding her responsibilities to lead the Global Innovative Pharma Portfolio in 2014. In these roles she drove Pfizer’s global regulatory development for vaccines, anti-infectives, inflammation, rare disease, neuroscience, pain, ophthalmology, cardiovascular, metabolic, renal and gender health.

Dr. Kahn joined Pfizer from GlaxoSmithKline (GSK) where she served in preclinical and clinical disposition and metabolism moving into international regulatory affairs and business development. She served in a series of Vice Presidential roles and supported a wide range of therapeutic areas at GSK including pulmonary, anti-infectives, oncology, cardiovascular, metabolic, urology with eleven years in vaccine development.

Dr. Kahn has a PhD in Biochemical Pharmacology from the Department of Clinical Pharmacology at The Royal Postgraduate Medical School, London and moved to Philadelphia to serve as Assistant Professor in the Departments of Pharmacology and Laboratory Medicine at the University of Pennsylvania. Dr. Kahn served on the Executive Committee of the Graduate Group in Pharmacological Sciences and retained an adjunct faculty position for several years after joining industry.

|John McMurray, MD

John McMurray, MD

Professor of Medical Cardiology, University of Glasgow

Professor McMurray served as the inaugural Eugene Braunwald Scholar in Cardiovascular (CV) Disease at the Brigham and Women’s Hospital, Boston, USA, and visiting Professor of Medicine, Harvard University, Boston, in 2010/2011. He is also Past-President of the Heart Failure Association of the European Society of Cardiology (ESC).

Professor McMurray’s primary research interest is in heart failure (HF) and his main research activity is clinical trials. He is, or was, the principal investigator, and member of the executive committee or steering committee in a number of large trials in HF, other CV diseases, renal disease and diabetes.

Professor McMurray sits on the editorial board of the New England Journal of Medicine. He has published approximately 600 original papers, reviews, and book chapters and was the lead author of the World Health Organization and first Scottish Intercollegiate Guidelines Network Guidelines on the Management of HF. In addition he was Co-Chair of the Kidney Disease Improving Global Outcomes Anemia Guidelines Committee; and member of the 2013 American College of Cardiology/American Heart Association HF Guidelines Committee. He is a member of the National Institute for Health and Care Excellence (NICE) Acute HF Guidelines Committee and was recently appointed to NICE (Appraisal Committee A). Professor McMurray was included in the 2014 listing of Highly Cited Researchers by Thomson-Reuters.

|Bertram (Bert) Pitt, MD

Bertram (Bert) Pitt, MD

Professor Emeritus, University of Michigan Medical School

Dr. Pitt’s research is in cardiovascular disease, with special emphasis on the ischemic heart disease and heart failure. He spent 15 years as the Director, Division of Cardiology at University of Michigan School of Medicine. Dr. Pitt has chaired or co-chaired a number of clinical trials in cardiology including SOLVD; ELITE I and II; PREVENT; RALES; EPHESUS; and TOPCAT and has published over 500 articles in peer reviewed journals.  Dr. Pitt has been a member of a numerous medical journal editorial boards and medical organizations, as well as served as an advisor to the clinical trials branch of the NHLBI and a member of the FDA cardio-renal advisory board.  He has been awarded the James B. Herrick Award by the Council of Clinical Cardiology of the American Heart Association. He is Diplomate of the American Board of Internal Medicine and of the American Board of Cardiology.

Dr. Pitt is a member of numerous professional societies and has held office in several of them. Among others, he was Chairman, Council on Circulation of the American Heart Association, Chairman, Young Investigator’s Award Committee of the American College of Cardiology, and is currently Chairman of the Reveal Committee of the ACC.

Dr. Pitt received his MD degree from the University of Basel, Switzerland.  He completed fellowship in cardiology at the Johns Hopkins University School of Medicine.

|Richard G. Wunderink, MD

Richard G. Wunderink, MD

Northwestern University Feinberg School of Medicine

Richard Wunderink is a Professor of Medicine in the Pulmonary and Critical Care Division of Northwestern University Feinberg School of Medicine and Medical Director of the MICU, Northwestern Memorial Hospital. Dr Wunderink has been active in research and education regarding on pulmonary infections, especially community-acquired pneumonia and ventilator-associated pneumonia, and sepsis. His research interests include prevention, diagnosis, risk stratification, and treatment, both antibiotic and adjunctive therapies, for these serious infectious diseases. He co-chaired the most recent IDSA/ATS Consensus Guidelines Committee on the management of community-acquired pneumonia. He was a member of the last American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) committee which developed guideline statements on hospital-acquired and healthcare-associated pneumonia and currently serves on the ERS/ ESCIM/ ESCMID/ ALAT Guidelines for the management of Hospital acquired pneumonia.

|Faiez Zannad, MD, PhD

Faiez Zannad, MD, PhD

 Center of Clinical Investigation, CIC, Inserm and University of Lorraine, CHU de Nancy, Nancy, France

 Faiez Zannad is Professor of Therapeutics at the University of Lorraine in Nancy, France. He earned his MD degree and cardiology specialty at the University of Lorraine in 1979 and his PhD degree in clinical pharmacology at the University of Lyon in Lyon, France, in 1984; during his PhD study, he also completed a fellowship at the MRC Clinical Pharmacology unit, Oxford, UK. Professor Zannad is currently Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux” in the Centre Hospitalier et Universitaire of Nancy.

Professor Zannad coordinates two EU FP7 grants in heart failure: HOMAGE (omics biomarkers for mechanistic phenotyping and prediction of drug response [www.homage‐hf.eu]) and FIBROTARGETS (fibrosis as a biotargets [www.fibrotargets.eu]). As the primary investigator or member of the oversight committees in major clinical trials, Professor Zannad has made significant contributions to evidence‐based heart failure life‐saving therapy, mainly with beta‐blockers (CIBIS) and mineralocorticoid receptor antagonists (RALES, EPHESUS, EMPHASIS‐HF). He pioneered cardiovascular outcome trials in chronic kidney disease (FOSIDIAL, AURORA, ALCHEMIST) and the one of the first cardiovascular safety trials on glucose‐lowering drugs in diabetes (EXAMINE). Professor Zannad has served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on pharmacology and drug therapy, and board member of the ESC Heart Failure Association. He was Founder and

is currently Chairman of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international meeting dedicated to the science of clinical trials, and of the International Workshop on Biomarkers in heart failure. As of July 2016, Professor Zannad has authored more than 530 scientific publications.